Purchase this article with an account.
E. R. Craven, A. L. Robin, R. M. Feldman, S. A. Scheib, J. E. Dickerson, T. A. Landry, D. T. Wells, A. F. Clark, M. V. W. Bergamini; Control of IOP in Open-Angle Glaucoma by Anecortave Acetate: A Comparison of Three Doses and Vehicle. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1207. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate (AA) ophthalmic suspension (3, 15, and 30 mg) compared to vehicle, administered as a single anterior juxtascleral depot (AJD) in patients with a clinical diagnosis of open-angle glaucoma (OAG).
This was a randomized double-masked multi-center (N=10) study. Eligible patients had a clinical diagnosis of OAG and eligibility IOP between 24 and 36 mmHg in the study eye. Qualifying patients were randomized to receive a single 0.5 mL AJD of anecortave acetate (3, 15, or 30 mg) or vehicle in the "worse" eye. The fellow, non-injected eye was treated with latanoprost. On-therapy visits were at 2, 6 and 12 weeks. Success was defined as an IOP 21 mmHg.
85 of 86 patients were evaluable by ITT. 42% of the patients were on multiple IOP-lowering medications prior to the study. Mean baseline IOP was similar across all four treatment groups for both eyes (range=27.1 to 28.3 mmHg, injected eye; 22.8 to 25.5 mmHg, fellow eye). At 3 months, the success rate (IOP 21 mmHg) was similar for the 3 and 15 mg groups (approximately 30%) and was 50% for the 30 mg group. This was about two-fold that seen for the vehicle group (24%). Patients considered treatment successes had similar mean IOP reductions in the study eye (regardless of dose) of -8, -6.7, and -7 mmHg for 3, 15, and 30 mg, respectively, compared to -1.4 mmHg for the vehicle treated group. Interestingly, mean IOP reductions for the latanoprost-treated fellow eyes ranged between -5 and -7 mmHg depending on the treatment group. The most common adverse events were eye pain, foreign body sensation, and blurred vision. Of the 14 reports of eye pain, 9 (64%) were related to the injection procedure.
This PDF is available to Subscribers Only